๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Inositol treatment of alzheimer's disease: A double bund, cross-over placebo controlled trial

โœ Scribed by Yoram Barak; Joseph Levine; Arie Glasman; Avner Elizur; Robert H Belmaker

Book ID
116120286
Publisher
Elsevier Science
Year
1996
Tongue
English
Weight
408 KB
Volume
20
Category
Article
ISSN
0278-5846

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Intravenous flumazenil for Parkinson's d
Intravenous flumazenil for Parkinson's disease: A single dose, double blind, placebo controlled, cross-over trial
โœ William G. Ondo; Yavuz S. Silay ๐Ÿ“‚ Article ๐Ÿ“… 2006 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 81 KB ๐Ÿ‘ 1 views

## Abstract Flumazenil is a shortโ€acting intravenously administered ฮณโ€aminobutyric acid (GABA) antagonist used to reverse the effects of benzodiazepines. Based upon current basal ganglion models in Parkinson's disease (PD), flumazenil could normalize neuronal signaling at several different location

A double-blind, placebo-controlled singl
A double-blind, placebo-controlled single dose trial of intravenous flumazenil in Alzheimer's disease
โœ Lisa Templeton; Andrew Barker; Keith Wesnes; David Wilkinson ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 203 KB ๐Ÿ‘ 2 views

Benzodiazepine agonists have been shown to reduce cognitive functioning by producing attentional deยฎcits similar to those produced by muscarinic antagonists. It has therefore been postulated that benzodiazepine antagonists may improve cognitive function in patients with Alzheimer's disease by indire